NRG And Curium Sign Contract For Production of Mo-99 NRG (ENS Corporate Member) and Curium have signed a multi-year contract for the production of molybdenum-99, the starting material for technetium-99m (Tc-99m). Tc-99m is the most used isotope in nuclear medicine for diagnosing life-threatening diseases, such as cardiovascular diseases, lung and brain disorders and cancer. With…
Framatome Announces New Investment Supporting Nuclear Medicine Framatome (ENS Corporate Member) announced that it acquired a minority stake in the French startup Global Morpho Pharma. With this investment, Framatome strengthens its activities serving nuclear medicine development and expands its support for the supply chain of Lutetium-177 and other promising isotopes for therapeutic applications. Global Morpho…
Ensuring The Future – Outlook on Medical Radioisotopes and Uranium Supply Chains in Europe Interview with Euratom Supply Agency Director General Agnieszka Kazmierczak Medical radioisotopes are a crucial tool in beating cancer and other diseases, offering several and innovative solutions in terms of diagnostics and treatments. Despite this key role, the whole production and supply…
The World’s First Lutetium-177 Produced At Commercial Nuclear Reactor The Canadian nuclear operator Bruce Power announced the world’s first production of lutetium-177 (Lu-177) at a commercial nuclear reactor, its Bruce-7 nuclear power plant in Ontario. This milestone has been achieved thanks to the international cooperation between Bruce Power, Isogen (a Kinectrics and Framatome company), and…
Radioisotopes for Life // Ensuring European Supply – Stakeholders and Opportunities The European Nuclear Society organised the webinar “Radioisotopes for life. Ensuring European supply – Stakeholders and opportunities”, in collaboration with Euratom Supply Agency, SCK CEN (both ENS Members), PALLAS and the EU Commission DG ENER. Speakers, moderated by Kristoff Muylle (former President of the…